T. Rowe Price Associates
CALC icon

T. Rowe Price Associates’s CalciMedica CALC Stock Holding History

T. Rowe Price Associates’s Portfolio CALC Stock Details CALC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,745
Closed -$1.15M – 2923
2021
Q1 		$1.15M Buy
+14,745
New +$4.41M ﹤0.01% 1996

Other funds holding CALC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

T. Rowe Price Associates's CALC Position: Q2 2021 in Review

T. Rowe Price Associates sold out of CalciMedica (CALC) in Q2 2021, closing a stake of 14,745 shares — an estimated $1.15M sold.

T. Rowe Price Associates first reported a position in CALC in Q1 2021 and held it in 1 quarter. The position peaked at $1.15M in Q1 2021. 41 funds tracked by Wall St. Rank hold CALC as of Q2 2021.

  • T. Rowe Price Associates reported no remaining CalciMedica position as of Q2 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 14,745 CalciMedica shares in Q2 2021, an estimated $1.15M.
  • T. Rowe Price Associates first reported a position in CalciMedica in Q1 2021 and held it in 1 quarter.
  • T. Rowe Price Associates's CalciMedica position peaked at $1.15M in Q1 2021.
  • 41 funds tracked by Wall St. Rank held CalciMedica as of Q2 2021.

Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.